Summit Therapeutics Inc. (SMMT) Form 8-K — Sep 28, 2026
Summit Therapeutics signed a securities purchase agreement on September 28, 2026 to sell 108,955.3686 Class A Convertible Preferred shares to AstraZeneca Holdings B.V. for $2.0 billion in gross proceeds, priced at $18.3561 per underlying common share. Each preferred share converts into 1,000 common shares, implying roughly 109 million new common shares once converted, and AstraZeneca receives preemptive rights and third-party acquisition participation rights. Conversion requires HSR clearance and a charter amendment increasing authorized common stock to at least 1.25 billion shares; if that amendment fails within 18 months, Summit must redeem the preferred at market value.
Key figures
- Gross Proceeds
- 2000000000
- Offering Price
- $18,356.14 per preferred share ($18.3561 per underlying common share)
- Shares Offered
- 108,955.3686 preferred shares (convertible into ~108,955,369 common shares)
- Conversion ratio
- 1,000 common shares per preferred share
- Amendment deadline
- 18 months from initial issue date
- Authorized share increase
- to not fewer than 1,250,000,000 common shares
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.